DCZ3301 是一种凋亡 (apoptosis) 诱导剂,可调控 JAK2/STAT3、ERK1/2 和 PI3K/AKT 信号通路,诱导细胞周期阻滞于 G2/M 期和 M 期,抑制细胞增殖与活力,增强 DNA 损伤,抑制 DNA 修复和血管生成,并可用于弥漫性大 B 细胞淋巴瘤、多发性骨髓瘤和白血病的研究。
产品编号: MS-Q14765 纯度: 99.73% CAS No.: 2136278-38-9 分子式: C20H16ClF3N6O2 分子量: 464.83
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

DCZ3301 是一种凋亡 (apoptosis) 诱导剂,可调控 JAK2/STAT3、ERK1/2 和 PI3K/AKT 信号通路,诱导细胞周期阻滞于 G2/M 期和 M 期,抑制细胞增殖与活力,增强 DNA 损伤,抑制 DNA 修复和血管生成,并可用于弥漫性大 B 细胞淋巴瘤、多发性骨髓瘤和白血病的研究。

生物实验数据

生物活性 DCZ3301 is an apoptosis inducer that modulates the JAK2/STAT3, ERK1/2, and PI3K/AKT signaling pathways, induces cell cycle arrest at G2/M and M phases, inhibits cell proliferation and viability, enhances DNA damage, suppresses DNA repair and angiogenesis, and can be used for research on diffuse large B-cell lymphoma, multiple myeloma, and leukemia.
IC50 & Target

JAK2

 

p-STAT3

 

ERK1

 

ERK2

 

体外研究
(In Vitro)

DCZ3301 (1-32 μM;48 小时) 可强效抑制 OCI-LY8、NU-DUL-1、SUDHL-4、DB 和 TMD8 这几种 DLBCL 细胞系的增殖。
DCZ3301 (1-32 μM;24-72 小时) 可以时间依赖的方式抑制 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系的增殖。
DCZ3301 (2-20 μM;48 小时) 可在 IL-6 或 IGF-1 存在的情况下抑制 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系的增殖,且这些促肿瘤细胞因子不会影响其生长抑制作用。
DCZ3301 (4-20 μM;24-72 小时) 可以剂量和时间依赖的方式诱导 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系发生凋亡。
DCZ3301 (8-16 μM;48 小时) 可通过外源性和内源性半胱天冬酶依赖通路诱导 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系发生凋亡。
DCZ3301 (4 μM; 8-24 小时) 可在 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系中诱导时间依赖性 G2/M 期细胞周期阻滞。
DCZ3301 (4-8 μM;24 小时) 可在 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系中调控细胞周期相关蛋白 (上调 p-CHK2 和 p21,下调 cdc25A、cdc25C 及 cyclinB1)。
DCZ3301 (8-16 μM;48 小时) 可在 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系中调控 Akt、ERK1/2 及 JAK2/STAT3 信号通路。
DCZ3301 (4-8 μM;24 小时) 在 STAT3 敲低的 OCI-LY8 和 NU-DUL-1 这两种 DLBCL 细胞系中增强抗增殖作用。
DCZ3301 (8-16 μM;12-48 小时) 可以剂量和时间依赖的方式抑制 Lyn 的磷酸化 (Y507),同时伴随 STAT3 磷酸化水平的相应降低。
DC50Z3301 (8-16 μM;48 小时) 可调控 BTZ 耐药的多发性骨髓瘤细胞 NCI-H929R 和 RPMI-8226R5 中 DNA 修复相关蛋白的表达。
DCZ3301 (8 μM;48 小时) 可上调 γ-H2A.X 的表达并在 BTZ 耐药多发性骨髓瘤细胞 NCI-H929R 和 RPMI-8226R5 中诱导 γ-H2A.X 灶形成,证实其可增强 DNA 损伤。
DCZ3301 (5 μM;24 小时) 可在伤口愈合实验中抑制人脐静脉内皮细胞 (HUVECs) 的迁移。

Cell Proliferation Assay

Cell Line: OCI-LY8, NU-DUL-1, SUDHL-4, DB, TMD8 (diffuse large B-cell lymphoma cell lines)
Concentration: 1 μM; 2 μM; 4 μM; 8 μM; 16 μM; 32 μM
Incubation Time: 48 h
Result: Caused a dose-dependent decrease in DLBCL cell proliferation.
Achieved IC50 values of 7.1 μM (OCI-LY8), 9.7 μM (NU-DUL-1), 6.67 μM (SUDHL-4), 8.04 μM (DB), and 9.66 μM (TMD8).

Cell Proliferation Assay

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 1 μM; 2 μM; 4 μM; 8 μM; 16 μM; 32 μM
Incubation Time: 24 h; 48 h; 72 h
Result: Inhibited proliferation of OCI-LY8 and NU-DUL-1 cells in a time-dependent manner, with greater inhibition observed at longer incubation times.

Cell Proliferation Assay

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 2 μM; 4 μM; 6 μM; 8 μM; 10 μM; 12 μM; 16 μM; 20 μM
Incubation Time: 48 h
Result: Induced growth inhibition that was not altered by the presence of IL-6 or IGF-1, despite these cytokines alone stimulating DLBCL cell growth.

Apoptosis Analysis

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 4 μM; 5 μM; 8 μM; 10 μM; 12 μM; 15 μM; 16 μM; 20 μM
Incubation Time: 24 h; 48 h; 72 h
Result: Induced apoptosis in OCI-LY8 and NU-DUL-1 cells in a dose- and time-dependent manner.
Increased apoptosis rates with higher concentrations and longer incubation times, with statistically significant increases compared to controls.

Western Blot Analysis

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 8 μM; 16 μM
Incubation Time: 48 h
Result: Caused a dose-dependent increase in cleaved caspase-3, caspase-8, caspase-9, and PARP, while downregulating Bcl-2 and Bcl-xL and upregulating Bax.
Suppressed apoptosis in NU-DUL-1 cells when pre-incubated with pan-caspase inhibitor Z-VAD-FMK.

Cell Cycle Analysis

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 4 μM
Incubation Time: 8 h; 12 h; 24 h
Result: Caused a time-dependent accumulation of cells in the G2/M phase in both OCI-LY8 and NU-DUL-1 cell lines, with statistically significant increases (P < 0.05, P < 0.001) compared to controls at 12 and 24 h.

Western Blot Analysis

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 4 μM; 8 μM
Incubation Time: 24 h
Result: Increased p-CHK2 and p21 protein expression, while decreasing protein levels of cdc25A, cdc25C, and cyclinB1 in both OCI-LY8 and NU-DUL-1 cells.

Western Blot Analysis

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 8 μM; 16 μM
Incubation Time: 48 h
Result: Upregulated phosphorylated ERK1/2, downregulated phosphorylated Akt, phosphorylated JAK2, and phosphorylated STAT3, and reduced c-Myc expression in a dose-dependent manner in both OCI-LY8 and NU-DUL-1 cells.

Cell Proliferation Assay

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines, STAT3 knockdown)
Concentration: 4, 8 μM
Incubation Time: 48 h
Result: Enhanced antiproliferative efficacy in STAT3-knockdown OCI-LY8 and NU-DUL-1 cells compared to negative control siRNA-transfected cells, with statistically significant differences (P < 0.05) observed at both concentrations.

Western Blot Analysis

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines)
Concentration: 8 μM; 16 μM
Incubation Time: 12 h; 24 h; 36 h; 48 h
Result: Downregulated phosphorylated Lyn (Y507) in a dose- and time-dependent manner, while having no effect on phosphorylated Syk.
Decreased phosphorylated Lyn correlated with a synchronous decrease in phosphorylated STAT3.

Western Blot Analysis

Cell Line: OCI-LY8, NU-DUL-1 (diffuse large B-cell lymphoma cell lines, Lyn-overexpressing)
Concentration: 16 μM
Incubation Time: 24 h
Result: Caused a greater suppression of phosphorylated STAT3 in Lyn-overexpressing cells compared to control cells after 24 h, despite Lyn-overexpressing cells exhibiting higher levels of phosphorylated STAT3 than control cells without treatment.

Immunofluorescence

Cell Line: BTZ-resistant multiple myeloma cell lines NCI-H929R and RPMI-8226R5
Concentration: 8 μM
Incubation Time: 48 h
Result: Increased γ-H2A.X expression and formation of γ-H2A.X foci, indicating increased DNA double-strand breaks.\nInduced the formation of multipolar mitotic spindles, a hallmark of mitotic catastrophe.
体内研究
(In Vivo)

DCZ3301 (40 mg/kg;腹腔注射;每日一次;连续 12 天) 可显著抑制 BALB/c 裸鼠中弥漫性大 B 细胞淋巴瘤异种移植瘤的生长。
DCZ3301 (50 mg/kg;腹腔注射;连续给药 2 天,随后给予溶媒 1 天;持续 20 天) 可显著抑制 BTZ 耐药多发性骨髓瘤异种移植模型中的肿瘤生长。
DCZ3301 (50 mg/kg;腹腔注射;每日一次;连续 14 天) 对健康 BALB/C 裸鼠无明显急性肝或肾毒性。
DCZ3301 (30 mg/kg;腹腔注射;每日一次;连续 14 天) 可显著抑制 BALB/c 裸鼠体内 T 细胞白血病/淋巴瘤异种移植瘤的生长。
DCZ3301 (30 mg/kg;腹腔注射;每日 1 次;连续 14 天) 可显著抑制 T 细胞白血病 Jurkat 细胞异种移植模型中的肿瘤生长并降低肿瘤重量。
DCZ3301 (50-200 μM;局部滴眼液;每日 3 次;连续 7 天) 可显著减小碱烧伤小鼠的角膜新生血管面积并减轻角膜基质水肿,与溶媒对照组相比,200 μM 时对 CNV 面积的减小作用更显著。
DCZ3301 (200 μM;局部滴眼液;每日 3 次;持续 7 天) 对健康 BALB/c 小鼠的角膜上皮厚度或内皮细胞密度无显著影响。

Animal Model: BALB/c nude (6-week-old male, athymic, nu/nu, subcutaneous xenograft model)
Dosage: 40 mg/kg
Administration: i.p.; daily; 12 days
Result: Reduced tumor volume significantly compared to controls by day 12 (P < 0.05).
Showed no significant difference in mouse body weight compared to controls.
Increased cell necrosis in tumor tissues via H&E staining.
Increased apoptotic cells in tumor tissues via TUNEL staining.
Downregulated phosphorylated STAT3 expression in tumor tissues via immunohistochemistry.
Showed no evidence of organ dysfunction or growth disorder in functional organs.
Animal Model: BALB/C nude mice (weight monitored during study)
Dosage: 50 mg/kg
Administration: i.p.; 2 consecutive days followed by 1 day of vehicle; for 20 days
Result: Significantly reduced tumor volume compared to control group on day 20.
Did not cause changes in mouse body weight or significant differences in serum levels of ALT, AST, Cr, or BUN.
Increased tumor cell shrinkage and fragmentation relative to controls.
Reduced Ki-67 expression in tumor tissue.
Increased cleaved-caspase 3 expression in tumor tissue.
Upregulated γ-H2A.X, phospho-ATM, and phospho-CHK1 expression in tumor tissue.
Increased percentage of TUNEL-positive cells in tumors.
Animal Model: BALB/C nude mice (weight monitored during study)
Dosage: 50 mg/kg
Administration: i.p.; daily; 14 days
Result: Showed no significant differences in serum levels of ALT, AST, Cr, or BUN compared to vehicle-treated controls.
Animal Model: BALB/c nude (5-week-old male, subcutaneous xenograft with Jurkat cells)
Dosage: 30 mg/kg
Administration: i.p.; daily; 14 days
Result: Reduced final tumor volumes to statistically significant levels (P < 0.01).
Reduced final tumor weights to statistically significant levels (P < 0.001).
Caused no significant change in mouse body weight compared to vehicle controls.
Animal Model: BALB/c nude (5-week-old male, subcutaneous xenograft model)
Dosage: 30 mg/kg
Administration: i.p.; daily; 14 days
Result: Reduced tumor volume by a statistically significant margin on days 12 and 14 of treatment (P < 0.01).
Lowered final tumor weight significantly compared to controls (P < 0.001).
Caused no significant change in mouse body weight compared to vehicle-treated groups.
Animal Model: BALB/c (6-8 week old male, alkali-burn induced corneal neovascularization)
Dosage: 50 μM; 200 μM
Administration: topical eye drops; three times daily; 7 days
Result: Significantly reduced the ratio of corneal neovascularization (CNV) area compared to vehicle control (P < 0.01).
Significantly reduced the ratio of CNV area compared to vehicle control (P < 0.0001).
Greatly reduced corneal stroma thickness compared to vehicle control (P < 0.001).
Greatly reduced corneal stroma thickness compared to vehicle control (P < 0.0001).
Animal Model: BALB/c
Dosage: 200 μM
Administration: topical eye drops; three times daily; 7 days
Result: Did not cause a significant difference in central corneal epithelial thickness compared to saline-treated controls (P > 0.05).
Did not cause a significant difference in corneal endothelial cell density compared to saline-treated controls (P > 0.05).
Maintained regular shape of corneal endothelial cells.
性状 固体
颜色 White to off-white

化学信息

分子量 464.83
分子式 C20H16ClF3N6O2
CAS No. 2136278-38-9

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.08 mg/mL (4.47 mM), Solution.
10% DMSO+90% Saline: < 2.08 mg/mL (4.47 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% Corn Oil: 2.5 mg/mL (5.38 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (107.57 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1513 mL10.7566 mL21.5132 mL53.7831 mL
5 mM0.4303 mL2.1513 mL4.3026 mL10.7566 mL
10 mM0.2151 mL1.0757 mL2.1513 mL5.3783 mL
15 mM0.1434 mL0.7171 mL1.4342 mL3.5855 mL
20 mM0.1076 mL0.5378 mL1.0757 mL2.6892 mL
25 mM0.0861 mL0.4303 mL0.8605 mL2.1513 mL
30 mM0.0717 mL0.3586 mL0.7171 mL1.7928 mL
40 mM0.0538 mL0.2689 mL0.5378 mL1.3446 mL
50 mM0.0430 mL0.2151 mL0.4303 mL1.0757 mL
60 mM0.0359 mL0.1793 mL0.3586 mL0.8964 mL
80 mM0.0269 mL0.1345 mL0.2689 mL0.6723 mL
100 mM0.0215 mL0.1076 mL0.2151 mL0.5378 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础